scholarly journals Neurological manifestations and neuro‐invasive mechanisms of the severe acute respiratory syndrome coronavirus type 2

2020 ◽  
Vol 27 (8) ◽  
pp. 1578-1587 ◽  
Author(s):  
K. Vonck ◽  
I. Garrez ◽  
V. De Herdt ◽  
D. Hemelsoet ◽  
G. Laureys ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Neurological Manifestations

scholarly journals Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19)

2021 ◽  
Author(s):  
Biyan Nathanael Harapan ◽  
Hyeon Joo Yoo
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Case Reports ◽  
Case Series ◽  
Altered Mental Status ◽  
Neurological Complications ◽  
Neurological Symptoms ◽  
Neurological Manifestations ◽  
Fisher Syndrome ◽  
Novel Coronavirus ◽  
The Impact

AbstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus, is responsible for the outbreak of coronavirus disease 19 (COVID-19) and was first identified in Wuhan, China in December 2019. It is evident that the COVID-19 pandemic has become a challenging world issue. Although most COVID-19 patients primarily develop respiratory symptoms, an increasing number of neurological symptoms and manifestations associated with COVID-19 have been observed. In this narrative review, we elaborate on proposed neurotropic mechanisms and various neurological symptoms, manifestations, and complications of COVID-19 reported in the present literature. For this purpose, a review of all current published literature (studies, case reports, case series, reviews, editorials, and other articles) was conducted and neurological sequelae of COVID-19 were summarized. Essential and common neurological symptoms including gustatory and olfactory dysfunctions, myalgia, headache, altered mental status, confusion, delirium, and dizziness are presented separately in sections. Moreover, neurological manifestations and complications that are of great concern such as stroke, cerebral (sinus) venous thrombosis, seizures, meningoencephalitis, Guillain–Barré syndrome, Miller Fisher syndrome, acute myelitis, and posterior reversible encephalopathy syndrome (PRES) are also addressed systematically. Future studies that examine the impact of neurological symptoms and manifestations on the course of the disease are needed to further clarify and assess the link between neurological complications and the clinical outcome of patients with COVID-19. To limit long-term consequences, it is crucial that healthcare professionals can early detect possible neurological symptoms and are well versed in the increasingly common neurological manifestations and complications of COVID-19.

scholarly journals A case series of ischemic stroke with coronavirus disease 2019 in two Egyptian centers

2020 ◽  
Vol 56 (1) ◽  
Author(s):  
Nevine El Nahas ◽  
Tamer Roushdy ◽  
Eman Hamid ◽  
Sherien Farag ◽  
Hossam Shokri ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Severe Acute Respiratory Syndrome ◽  
Cerebrovascular Disorders ◽  
Case Series ◽  
Neurological Manifestations ◽  
Case Presentation ◽  
Novel Virus

Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel virus that has been reported to have various neurological manifestations. Cerebrovascular disorders have been encountered as a coronavirus disease 2019 (COVID-19) presentation in our center during the pandemic. Case presentation We are presenting 10 cases with cerebrovascular manifestations after having COVID-19 few days prior to stroke. Conclusion Cerebrovascular manifestations can occur in association with COVID-19 and may have significant implications on prognosis and management.

scholarly journals Prähospitaler Kreislaufstillstand im Lockdown

2021 ◽  
Author(s):  
T. Grübl ◽  
B. Plöger ◽  
M. C. Sassen ◽  
A. Jerrentrup ◽  
B. Schieffer ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Sich Eine ◽  
Retrospektive Analyse ◽  
Neurologisches Outcome

Zusammenfassung Hintergrund Das SARS-CoV‑2 (Severe acute respiratory syndrome coronavirus type 2) hat sich weltweit ausgebreitet. Folgen von Infektionspräventionsmaßnahmen im Rahmen solcher Ansteckungsereignisse können speziell für Patienten mit außerklinischem Kreislaufstillstand (OHCA) Nachteile ergeben. Methodik Retrospektive Analyse von OHCA eines Landkreises in den Monaten Januar bis einschließlich Mai von 2018 bis 2020, wobei in 2020 die erste Welle der SARS-CoV-2-Pandemie und in 2018 eine Hochinzidenzphase des Influenzavirus vorlag. Ergebnisse N = 497 OHCA wurden untersucht (2018 n = 173, 2019 n = 149, 2020 n = 175). Es zeigte sich eine gleichbleibende Reanimationsinzidenz (85–99 Reanimationen/100.000 Einwohner/Jahr) und eine lokal typische Klientel („mean“ 70 Jahre, 66 % männlich; Median PES 3). Es ergaben sich keine statistisch signifikanten Unterschiede bei der Ausgangslage der Patienten (Anzahl beobachteter OHCA, Häufigkeit an Laienreanimationen, vermutete Ursachen des OHCA, initialer EKG-Rhythmus) und dem Behandlungsverlauf (Häufigkeit an ROSC/Krankenhausaufnahme/Überleben bis Krankenhausentlassung, neurologisches Outcome). Keiner der OHCA-Patienten in 2020 bot ein positives SARS-CoV-2- und drei Patienten in 2018 ein positives Influenzatestergebnis. Diskussion Die Lockdown-Maßnahmen während der ersten SARS-CoV-2-Welle scheinen das Outcome von OHCA-Patienten ohne COVID-19 insgesamt nicht beeinflusst zu haben.

scholarly journals Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 99
Author(s):  
Johann Sellner ◽  
Paulus S. Rommer
Keyword(s):  
Multiple Sclerosis ◽  
Severe Acute Respiratory Syndrome ◽  
Open Questions ◽  
Immunological Effects ◽  
Restricted Use

Several concerns have been raised about the use of immunodepleting agents including alemtuzumab, cladribine and CD20-depleting antibodies in people with multiple sclerosis (pwMS) during the coronavirus disease (COVID) 2019 pandemic. As the end of the pandemic is not yet in sight, vaccination against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) may be an elegant strategy to overcome the potential hazards associated with initiating and continuing treatment with immune-depleting agents. In this review, we summarize the immunological effects of immune-depleting therapy and underlying considerations for the hitherto existing recommendations that suggest a restricted use of immune-deleting therapies during the pandemic. Moreover, we critically discuss open questions regarding vaccination in general and against SARS-CoV-2 in pwMS.

scholarly journals Neurological Manifestations of COVID-19 patients: An Updated Review and Observations of COVID Patients in the National Institute of Neurosciences and Hospital, Dhaka, Bangladesh

2020 ◽  
pp. 122-132
Author(s):  
Mohammad Enayet Hussain ◽  
Md Azharul Hoque ◽  
Md Badrul Alam ◽  
Md Abdullah Yusuf ◽  
Rajib Nayan Chowdhury ◽  
...  
Keyword(s):  
Nervous System ◽  
Severe Acute Respiratory Syndrome ◽  
Viral Infection ◽  
Clinical Manifestation ◽  
Early Experience ◽  
Neurological Manifestations ◽  
Recent Outbreak ◽  
Near Future

Involvement of the nervous system after viral infection is common. Certain viruses show neurotropism. Recent outbreak of severe acute respiratory syndrome CoV 2 (SARSCov- 2) virus has also exhibited neurotropic properties with various neurological manifestations. The pathophysiology of their neurotropism is not yet clearly known. The details of pathophysiology, clinical manifestation and management are expected to be explored in the near future. Here we review the Neurological manifestations of COVID-19 and the early experience in the National Institute of Neurosciences and Hospital. J Bangladesh Coll Phys Surg 2020; 38(0): 122-132

scholarly journals METFORMIN USE IN DIABETES PRIOR TO HOSPITALIZATION: EFFECTS ON MORTALITY IN COVID-19

2020 ◽  
Vol 26 (10) ◽  
pp. 1166-1172
Author(s):  
Jinghong Li ◽  
Qi Wei ◽  
Willis X. Li ◽  
Karen C. McCowen ◽  
Wei Xiong ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Severe Acute Respiratory Syndrome ◽  
Angiotensin Converting Enzyme ◽  
Clinical Data ◽  
Laboratory Data ◽  
Converting Enzyme ◽  
Angiotensin Converting Enzyme 2

Objective: Although type 2 diabetes mellitus (T2DM) has been reported as a risk factor for coronavirus disease 2019 (COVID-19), the effect of pharmacologic agents used to treat T2DM, such as metformin, on COVID-19 outcomes remains unclear. Metformin increases the expression of angiotensin converting enzyme 2, a known receptor for severe acute respiratory syndrome coronavirus 2. Data from people with T2DM hospitalized for COVID-19 were used to test the hypothesis that metformin use is associated with improved survival in this population. Methods: Retrospective analyses were performed on de-identified clinical data from a major hospital in Wuhan, China, that included patients with T2DM hospitalized for COVID-19 during the recent epidemic. One hundred and thirty-one patients diagnosed with COVID-19 and T2DM were used in this study. The primary outcome was mortality. Demographic, clinical characteristics, laboratory data, diabetes medications, and respiratory therapy data were also included in the analysis. Results: Of these 131 patients, 37 used metformin with or without other antidiabetes medications. Among the 37 metformin-taking patients, 35 (94.6%) survived and 2 (5.4%) did not survive. The mortality rates in the metformin-taking group versus the non-metformin group were 5.4% (2/37) versus 22.3% (21/94). Using multivariate analysis, metformin was found to be an independent predictor of survival in this cohort ( P = .02). Conclusion: This study reveals a significant association between metformin use and survival in people with T2DM diagnosed with COVID-19. These clinical data are consistent with potential benefits of the use of metformin for COVID-19 patients with T2DM. Abbreviations: ACE2 = angiotensin-converting enzyme 2; AMPK = AMP-activated protein kinase; BMI = body mass index; COVID-19 = coronavirus disease 2019; SARSCoV-2 = severe acute respiratory syndrome coronavirus 2; T2DM = type 2 diabetes mellitus

scholarly journals The Myocardial and Neuronal Infectivity of SARS-CoV-2 and Detrimental Outcomes

2021 ◽  
Author(s):  
Ernest Herbert ◽  
Dominique Fournier ◽  
Waleed A. Al-Shaqha ◽  
Mohamed Chahine
Keyword(s):  
Risk Factors ◽  
Cardiovascular Risk ◽  
Severe Acute Respiratory Syndrome ◽  
Hospital Mortality ◽  
Early Stage ◽  
Neurological Complications ◽  
Insufficient Data ◽  
Neurological Manifestations ◽  
Characteristic Features ◽  
Neuronal Functions

The epidemiological outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), alias COVID-19, began in Wuhan, Hubei, China, in late December and eventually turned into a pandemic that has led to 3.71+ million deaths and 173+ million infected cases worldwide. In addition to respiratory manifestations, COVID-19 patients with neurological and myocardial dysfunctions exhibit a higher risk of in-hospital mortality. The immune function tends to be affected by cardiovascular risk factors and is thus indirectly related to the prognosis of COVID-19 patients. Many neurological symptoms and manifestations have been reported in COVID-19 patients. However, detailed descriptions of the prevalence and characteristic features of these symptoms are restricted due to insufficient data. It is thus advisable for clinicians to be vigilant for both cardiovascular and neurological manifestations in order to detect them at an early stage to avoid inappropriate management of COVID-19 and to address the manifestations adequately. Patients with severe COVID-19 are notably more susceptible to developing cardiovascular and neurological complications than non-severe COVID-19 patients. This review focuses on the consequential outcomes of COVID-19 on cardiovascular and neuronal functions, including other influencing factors.

scholarly journals COVID-19-Patientinnen und -Patienten in Deutschland: Expositionsrisiken und assoziierte Faktoren für Hospitalisierungen und schwere Krankheitsverläufe

2021 ◽  
Author(s):  
Uwe Koppe ◽  
Hendrik Wilking ◽  
Thomas Harder ◽  
Walter Haas ◽  
Ute Rexroth ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Narrative Review ◽  
Stationäre Behandlung ◽  
Trisomie 21

ZusammenfassungDas Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) hat sich seit 2020 weltweit verbreitet. In Deutschland haben sich bis zum Ende Juni 2021 über 3,7 Mio. Menschen infiziert. Das Infektionsgeschehen betrifft jedoch nicht alle Bevölkerungsgruppen gleichmäßig. Einige Gruppen haben ein besonders hohes Risiko, sich zu infizieren oder nach der Infektion schwere Coronavirus-Disease-2019(COVID-19)-Verläufe zu erleiden.Der vorliegende narrative Review vermittelt eine Übersicht über die Bevölkerungsgruppen in Deutschland, welche besonders von COVID-19 betroffen sind. Außerdem werden die bisher identifizierten Risikofaktoren beschrieben, die mit Krankenhausaufenthalten oder schweren COVID-19-Verläufen assoziiert sind.SARS-CoV-2-Übertragungen finden an den verschiedensten Orten und in unterschiedlichen Situationen statt. Besonders betroffen erscheinen bestimmte berufliche Umgebungen, wie z. B. die Fleisch verarbeitende Industrie, aber auch Freizeitaktivitäten und Großveranstaltungen. Es wurden im Laufe der Pandemie Komorbiditäten identifiziert, die mit einem erhöhten Hospitalisierungsrisiko oder einem schweren COVID-19-Verlauf assoziiert sind, z. B. vorbestehende Lungen‑, Herz-Kreislauf- und Stoffwechselkrankheiten. Patientinnen und Patienten nach Organtransplantation und Personen mit Downsyndrom (Trisomie 21) haben nach einer SARS-CoV-2-Infektion das höchste Risiko für eine stationäre Behandlung.Die identifizierten Rahmenbedingungen, die eine SARS-CoV-2-Verbreitung begünstigen, und das Wissen um besonders vulnerable Bevölkerungsgruppen bilden eine wichtige Evidenzgrundlage für die Planung von Präventionsstrategien und Maßnahmen zur Pandemiebekämpfung.

Sign in / Sign up

Export Citation Format

Share Document